Evidence map›Paper›PMID 38258057›Full record

ArticlePharmaceutics2023

Formulation and Evaluation of Insulin-Loaded Sodium-Alginate Microparticles for Oral Administration.

Ildikó Bácskay, Boglárka Papp, Péter Pártos, István Budai, Ágota Pető, Pálma Fehér, Zoltán Ujhelyi, Dóra Kósa

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Preparation and Investigation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Article
  4. Pulmonary delivery of insulin by dry powder inhaler formulations.Iranian journal of basic medical sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Ildikó BácskayDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-8663-2890
Boglárka PappDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.ORCID 0009-0005-1750-4496
Péter PártosDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.
István BudaiFaculty of Engineering, University of Debrecen, Ótemető Utca 2-4, 4028 Debrecen, Hungary.ORCID 0000-0002-8966-3817
Ágota PetőDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.ORCID 0000-0002-1326-5708
Pálma FehérDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.
Zoltán UjhelyiDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.ORCID 0000-0001-9724-0614
Dóra KósaDepartment of Pharmaceutical Technology, Faculty of Pharmacy, University of Debrecen, Nagyerdei Körút 98, 4032 Debrecen, Hungary.ORCID 0000-0002-7377-749X
University of Debrecen · HU

Funding

European Union and the European Regional Development Fund GINOP-2.3.1-20-2020-00004European Union and the European Regional Development Fund GINOP-2.3.4-15-2016-00002Ministry for Innovation and Technology ÚNKP-22-4-I National Excellence ProgramMinistry of Culture and Innovation of Hungary TKP2021-EGA-19
6 · The paper itself

Abstract

The development of oral insulin drug delivery systems is still an ongoing challenge for pharmaceutical technology researchers, as the formulation process has to overcome a number of obstacles due to the adverse characteristics of peptides. The aim of this study was to formulate different sodium-alginate microparticles as a possible method for oral insulin administration. In our previous studies, the method has been successfully optimized using a small model peptide. The incorporation of insulin into alginate carriers containing nonionic surfactants has not been described yet. In order to enhance the absorption of insulin through biological barriers, Labrasol ALF and Labrafil M 2125 CS were selected as permeation-enhancing excipients. They were applied at a concentration of 0.10% (

Indexed as

absorption enhancementCaco-2 cellsLabrafil M 2125 CSLabrasol ALFmicrobeadoral bioavailability

Identifiers

PMID38258057
PMCPMC10819542
OpenAlexW4390347780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.